ANTIBODIES CAPABLE OF BINDING SPECIFICALLY TO HER2

摘要

The present invention relates to a novel HER2 antibody for simultaneous administration used in preventing or treating cancer. The antibody of the present invention is an antibody which specifically bonds with HER2 which is over-expressed in cancer cells (especially, breast cancer cells and stomach cancer cells). The antibody of the present invention bonds with epitope separately from trastuzumab. Compared to the CDR sequences of the existing HER2 target antibodies, the antibody of the present invention has very low homogeny such that the sequence is peculiar. When the antibody of the present invention is simultaneously administrated with trastuzumab, cancer cells are killed by remarkably improved cancer cell killing functions, such that cancer (especially, breast cancer and stomach cancer) can effectively be prevented or treated. The excellence of simultaneous administration by the means of the antibody of the present invention is to control HER2 cooperatively with trastuzumab by bonding the antibody of the present invention with epitope on HER2 which is different from trastuzumab in a range which is not theoretically restricted (without wishing to be bound by theory).